Presentations

This invited talk shows how IgG suppresses IgE-mediated itch by blocking TRPV-1 neuron firing. This inhibition occurs through the activation of macrophage effector cells, highlighting neuro-immune communication in itch control.

Macrophages engage in cross-talk with neurons and immune cells to suppress the inflammatory signaling triggered by IgE during allergic responses. This protective neuroimmune pathway highlights macrophages as key regulators that counterbalance allergen-driven pathology.

This invited talk explains how a specific interaction between IgG antibodies and macrophages can reduce itching caused by IgE-allergen complexes. It highlights the protective role of macrophages in calming allergic itch responses.

IgG’s immune-modulating role can be both beneficial and detrimental. It helps reduce allergic inflammation and promotes tolerance but can also trigger harmful immune activation, increasing inflammation or tissue damage. This balance is key to understanding IgG’s impact on allergy outcomes.

Antibody glycosylation, the addition of sugar molecules to antibodies, shapes how these immune proteins interact with receptors and immune cells. Changes in IgE and IgG glycosylation can alter signaling pathways that drive or suppress itch responses in allergic disease.

Monoclonal antibody N-linked glycosylation monitoring during upstream bioprocessing is crucial for ensuring drug quality and efficacy. Real-time glycosylation data help detect variations early, allowing timely adjustments to the production process. This improves product consistency, safety, and therapeutic effectiveness, ultimately enhancing biomanufacturing efficiency and patient outcomes.

We showcase how the N-GLYcanyzer platform can be implemented at-/online in an upstream bioreactor for automated and near-real-time glycosylation monitoring of a Trastuzumab biosimilar produced by Chinese hamster ovary cells.

This toolkit can be used to understand the temporal changes of N-linked glycosylation during fed-batch and perfusion based mAb manufacturing allowing for tighter control of the glycan profile, leading to less variability during upstream bioprocessing.